Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • EAACI 2026

European Academy of Allergy and Clinical Immunology (EAACI) - 44th Annual Congress - 2026

June 12 - 15, 2026

  1. All
  2. FASENRA (benralizumab)
  3. TEZSPIRE (tezepelumab)
  4. SYMBICORT
  5. Respiratory Unbranded

PDF

Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial​

HTML

Reduction in OCS cumulative dose while improving asthma control and quality of life in severe eosinophilic asthma treated with Benralizumab. Real-World Evidence from the AURORA study

HTML

Immune markers after one year treatment with benralizumab in severe eosinophilic asthma

HTML

Efficacy of benralizumab in Chinese patients with severe eosinophilic asthma: subgroup analysis of the 16-week results from STEP, a phase IIIb study of step-down maintenance therapy

PDF

Tezepelumab reduces urine levels of eicosanoid metabolites indicative of mast cell activation in patients with moderate to severe, uncontrolled asthma: results from the phase 2 CASCADE Trial

PDF

Inhibitory effects of tezepelumab on proinflammatory mediators in nasal lining fluid from patients with CRSwNP in the phase 3 WAYPOINT study​

HTML

Response to tezepelumab treatment among adults with uncontrolled chronic rhinosinusitis with nasal polyps: week 76 off-treatment results from the phase 3 WAYPOINT study

HTML

Clinical outcomes and biomarker levels after cessation of tezepelumab treatment in adults with severe CRSwNP from WAYPOINT

HTML

Early and clinically meaningful improvements in nasal polyp symptoms following tezepelumab treatment in adults with chronic rhinosinusitis with nasal polyps: interim results from the phase 3b ESSENCE study

HTML

Changes in respiratory infections patterns in Patients with Severe Asthma and a High burden of comorbidities treated with tezepelumab: interim analysis results of the T-ROSS II study

HTML

Real-world assessment of tezepelumab in patients with severe asthma and chronic rhinosinusitis in France: preliminary results from the retrospective ROSE study

HTML

Tezepelumab reduces in patients with severe allergic asthma and rhinoconjunctivitis not only bronchial but also nasal and conjunctival symptoms - results from an exposure chamber study

HTML

Efficacy of tezepelumab in Chinese patients with severe uncontrolled asthma and comorbidities: a post-hoc analysis of the DIRECTION study

HTML

Response to eight-week budesonide-formoterol treatment in patients with chronic cough: results from the multicenter, prospective EFFICIENCY study

HTML

Characterization of CRSwNP and associated Type 2 or Respiratory comorbidities in the biological era in Spain - The POLARIS study

HTML

Clinical and demographic characteristics associated with a classification as difficult-to-treat asthma: data from the EPI-ASTHMA study

HTML

Unified airway profiling reveals shared and distinct features in T2-high asthma and nasal polyposis by mass cytometry

HTML

Patient characteristics and treatment patterns in adults with severe asthma in Poland (POLSAR): a retrospective, single-center real world cohort from ISAR

PDF

Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial​

HTML

Reduction in OCS cumulative dose while improving asthma control and quality of life in severe eosinophilic asthma treated with Benralizumab. Real-World Evidence from the AURORA study

HTML

Immune markers after one year treatment with benralizumab in severe eosinophilic asthma

HTML

Efficacy of benralizumab in Chinese patients with severe eosinophilic asthma: subgroup analysis of the 16-week results from STEP, a phase IIIb study of step-down maintenance therapy

PDF

Tezepelumab reduces urine levels of eicosanoid metabolites indicative of mast cell activation in patients with moderate to severe, uncontrolled asthma: results from the phase 2 CASCADE Trial

PDF

Inhibitory effects of tezepelumab on proinflammatory mediators in nasal lining fluid from patients with CRSwNP in the phase 3 WAYPOINT study​

HTML

Response to tezepelumab treatment among adults with uncontrolled chronic rhinosinusitis with nasal polyps: week 76 off-treatment results from the phase 3 WAYPOINT study

HTML

Clinical outcomes and biomarker levels after cessation of tezepelumab treatment in adults with severe CRSwNP from WAYPOINT

HTML

Early and clinically meaningful improvements in nasal polyp symptoms following tezepelumab treatment in adults with chronic rhinosinusitis with nasal polyps: interim results from the phase 3b ESSENCE study

HTML

Changes in respiratory infections patterns in Patients with Severe Asthma and a High burden of comorbidities treated with tezepelumab: interim analysis results of the T-ROSS II study

HTML

Real-world assessment of tezepelumab in patients with severe asthma and chronic rhinosinusitis in France: preliminary results from the retrospective ROSE study

HTML

Tezepelumab reduces in patients with severe allergic asthma and rhinoconjunctivitis not only bronchial but also nasal and conjunctival symptoms - results from an exposure chamber study

HTML

Efficacy of tezepelumab in Chinese patients with severe uncontrolled asthma and comorbidities: a post-hoc analysis of the DIRECTION study

HTML

Response to eight-week budesonide-formoterol treatment in patients with chronic cough: results from the multicenter, prospective EFFICIENCY study

HTML

Characterization of CRSwNP and associated Type 2 or Respiratory comorbidities in the biological era in Spain - The POLARIS study

HTML

Clinical and demographic characteristics associated with a classification as difficult-to-treat asthma: data from the EPI-ASTHMA study

HTML

Unified airway profiling reveals shared and distinct features in T2-high asthma and nasal polyposis by mass cytometry

HTML

Patient characteristics and treatment patterns in adults with severe asthma in Poland (POLSAR): a retrospective, single-center real world cohort from ISAR

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States